← Back to Search

Antiviral

VRx-3996 for Lymphoma

Phase 1 & 2
Waitlist Available
Research Sponsored by Viracta Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 2 years
Awards & highlights

Study Summary

This trial is testing a new drug to see if it's effective in treating lymphoma.

Eligible Conditions
  • Lymphoma
  • Lymphoproliferative Disorders

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Dose Limiting Toxicities in Dose Escalation and Cohort Expansion
Incidence of adverse events and changes in clinical safety laboratory values in Dose Escalation and Cohort Expansion
ORR as measured by stable disease (SD), partial response (PR), and complete response (CR) by radiographic assessment
Secondary outcome measures
Duration of response
Progression-free survival
Single-dose and steady-state AUC of VRx-3996 and valganciclovir
+3 more

Side effects data

From 2015 Phase 4 trial • 40 Patients • NCT01509404
50%
Leukopenia
30%
Acute rejection
25%
BK infection
20%
CMV disease
15%
Candidiasis
5%
Thrombocytopenia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Valcyte Then Cytogam
Valcyte

Trial Design

3Treatment groups
Experimental Treatment
Group I: Phase 2 Dose ExpansionExperimental Treatment2 Interventions
VRx-3996 (RP2D: recommended phase 2 dose) and valganciclovir
Group II: Phase 1b Dose EscalationExperimental Treatment2 Interventions
VRx-3996 (cohort 1) and valganciclovir VRx-3996 (cohort 2) and valganciclovir VRx-3996 (cohort 3) and valganciclovir VRx-3996 (cohort 4) and valganciclovir VRx-3996 (cohort 5) and valganciclovir
Group III: PK CohortExperimental Treatment2 Interventions
Assessment of VRx-3996 tablet and valganciclovir PK parameters at the RP2D
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Valganciclovir
FDA approved
Nanatinostat
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Viracta Therapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
284 Total Patients Enrolled
1 Trials studying Lymphoma
140 Patients Enrolled for Lymphoma
Jill DeFratis RobinsonStudy DirectorViracta Therapeutics
Robert McRaeStudy DirectorViracta Therapeutics

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies
2018. "Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03397706.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top